Imiquimod
Contents
Description
Imiquimod is a topical immune response modifier used to treat superficial basal cell carcinoma, actinic keratosis, and external genital warts. It can be used for benign skin lesions including certain benign tumors of the eyelid epidermis. The drug works by stimulating local immune responses through toll-like receptor 7 activation.
Indications & Therapeutic Use
Superficial basal cell carcinoma, Actinic keratosis, External genital warts, Benign epidermal lesions
Linked Diseases:
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Imiquimod — GNH India
28 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | Imiquimod |
| Brands | 1 brand available |
| Active Ingredient | Imiquimod |
| Drug Class | Superficial basal cell carcinoma |
| Manufacturer | 3M Pharmaceuticals |
| Dosage Forms | Topical cream 5% |
| Medical Code | D06BB10 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 10 days |
| Reg. Status | FDA Approved |
| Countries | 8 countries |